NasdaqGM:PRCTMedical Equipment
A Look At PROCEPT BioRobotics (PRCT) Valuation As AUA Guideline Update Expands Aquablation Opportunity
PROCEPT BioRobotics (PRCT) is back in the spotlight after updated American Urological Association guidelines strengthened support for its Aquablation therapy in treating benign prostatic hyperplasia, including patients with larger prostates.
See our latest analysis for PROCEPT BioRobotics.
The latest guideline update and recent Q1 report come against a mixed trading backdrop, with a 7 day share price return of 2.83% but a 1 year total shareholder return that has declined 55.02%. This suggests...